Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
mGlu2 PAM
- Development stage
- Preclinical
- Lead developer
- Janssen Pharmaceutical
- Modality
- Small Molecules
- Administration
- Oral, Subcutaneous, Intraperitoneal
01
Overview
mGlu2 PAM is a small molecule positive allosteric modulator of the metabotropic glutamate receptor 2 (mGlu2) currently in the lead optimization stage at the Warren Center for Neuroscience Drug Discovery (WCNDD). The program is specifically focused on the treatment of Parkinson's Disease. As a positive allosteric modulator, the drug candidate binds to an allosteric site on the mGlu2 receptor, enhancing the receptor's response to its endogenous ligand, glutamate. This mechanism is intended to provide more physiological modulation of glutamatergic signaling compared to orthosteric agonists, potentially offering a better safety profile and reduced receptor desensitization while addressing the neurochemical imbalances associated with Parkinson's Disease.
- Other names
- mGlu2 positive allosteric modulatormGlu-2 positive allosteric modulatormGlu 2 positive allosteric modulatormGlu2 PAM programmGlu-2 PAM programmGlu 2 PAM program
02
Targets
GRM2 (mGluR2)
Beyond the preview
Go deeper on mGlu2 PAM.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on mGlu2 PAM.